Ian Tzeng, a Managing Director and Partner in L.E.K.’s Boston office, joined the company in 1998 with experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He focuses on healthcare and life sciences, including pharmaceuticals, vaccines and medical devices. He leads L.E.K.’s Pharmaceutical Contract Services practice, including CROs, CDMOs, supply chain and distribution, commercial, medical, and market access services. Other areas of deep experience include rare diseases, biodefense, biosimilars and generics, and consumer-directed healthcare. Additionally, Ian has extensive consulting and board experience with nonprofit organizations in education, arts, LGBT advocacy and public service. He received a Bachelor of Arts degree, magna cum laude, in chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.

Education

Undergraduate: Bachelor of Arts in Chemistry, Harvard College

Graduate: Master of Business Administration, Harvard Business School

Ian's Expertise

Read More

Related Insights

Raising Orphans: How Pharma Can Capture Value While Treating Rare Diseases

L.E.K.'s Ian Tzeng looks at the changing dynamics of the orphan drug market and identifies winning strategies designed to capture value within this sector.
 
Pharma Capturing Value video thumbnail
Life Sciences & Pharma

Raising Orphans: How Pharma Can Capture Value While Treating Rare Diseases